Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 14/20 | 0.58 |
| ▸ | ABL1 | P00519 | 3/20 | 0.40 |
| ▸ | BCR | P11274 | 3/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20447425 | 0.89 | AAK1 (0.46) | AAK1ABL1BCRPDGFRBPDGFRA | |
| SCHEMBL21508206 | 0.87 | AAK1 (0.59) | AAK1ABL1BCR | |
| SCHEMBL21508477 | 0.82 | AAK1 (0.59) | AAK1ABL1BCRPIK3C3SRC | |
| SCHEMBL21508471 | 0.79 | AAK1 (0.58) | AAK1ABL1 | |
| SCHEMBL28487905 | 0.77 | KMO (0.39) | AAK1 | |
| SCHEMBL21508541 | 0.77 | AAK1 (0.69) | AAK1 | |
| SCHEMBL21508680 | 0.76 | AAK1 (0.66) | AAK1 | |
| SCHEMBL20446748 | 0.75 | AAK1 (0.56) | AAK1ABL1BCRPIK3C3 | |
| SCHEMBL20447482 | 0.75 | KMO (0.45) | AAK1ABL1BCRPDGFRBPDGFRA | |
| SCHEMBL21508497 | 0.74 | AAK1 (0.56) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112142655-A | Biaryl kinase inhibitors | 百时美施贵宝公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-108368084-B | Biaryl kinase inhibitors | 百时美施贵宝公司 | 2020-10-16 | — | — | CN | disclosed |
| US-10544120-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-28 | — | — | US | disclosed |
| EP-3356340-B1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3356340-A1 | BIARYL KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2018-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544120-B2 | Biaryl kinase inhibitors | AAK1, CAMKK1, CAMKK2 | AAK1 1/4885ABL1 172/4885BCR 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.